June 10, 2025

Does Combination Therapy Improve Albuminuria?

Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.

Conexiant

June 10, 2025

Does Autism-Linked Cortical Noise Impair Sleep?

New research presented at SLEEP 2025 links increased auditory cortex excitability with poor sleep efficiency in children—especially those with autism spectrum disorder—offering insight into sensory-driven sleep disturbances.

Conexiant

June 06, 2025

New Global Criteria Define Pediatric Bone Disease

An international team developed and validated the first global classification criteria for pediatric chronic nonbacterial osteomyelitis, offering a standardized tool to improve research and diagnosis.

Conexiant

June 03, 2025

FDA Grants Breakthrough Status to Shield Test

The methylation-based blood assay is designed for screening multiple cancer types.

Conexiant

June 03, 2025

Phytosterols May Shield Against Diabetes, CVD

Large Harvard study shows higher phytosterol intake, particularly beta-sitosterol, reduces type 2 diabetes and cardiovascular disease risk by up to 9%.

Conexiant

May 30, 2025

Extra Boost Before Surgery Shows Promise

Tevimbra added to chemo before esophageal cancer surgery doubled complete response rates in a phase 2 trial, hinting at a future shift in standard care.

Reuters

May 20, 2025

ICU Sedation Economics: A $1 Difference

Study finds dexmedetomidine, clonidine, and propofol have comparable cost-effectiveness for critically ill patients on mechanical ventilation.

Conexiant

May 19, 2025

Could New COPD Criteria Double Diagnosis Rates?

Multidimensional schema incorporating CT imaging and symptoms identifies high-risk patients without traditional airflow obstruction.

Conexiant

May 06, 2025

Shorter Prostate Radiotherapy Proves Long-Term Match

Two-week radiation treatment for localized prostate cancer delivers equivalent 10-year outcomes to standard 8-week course in a clinical trial.

Conexiant